Abstract:Background: Despite the introduction of targeted therapies, most patients with myeloid malignancies will not be cured and progress. Genomics is useful to elucidate the mutational landscape but remains limited in the prediction of therapeutic outcome and identification of targets for resistance. Dysregulation of phosphorylation-based signaling pathways is a hallmark of cancer, and therefore, kinase-inhibitors are playing an increasingly important role as targeted treatments. Untargeted phosphoproteomics analysis pipelines have been published but show limitations in inferring kinase-activities and identifying potential biomarkers of response and resistance. Methods: We developed a phosphoproteomics workflow based on titanium dioxide phosphopeptide enrichment with subsequent analysis by liquid chromatography tandem mass spectrometry (LC-MS). We applied a novel Kinase-Activity Enrichment Analysis (KAEA) pipeline on differential phosphoproteomics profiles, which is based on the recently published SetRank enrichment algorithm with reduced false positive rates. Kinase activities were inferred by this algorithm using an extensive reference database comprising five experimentally validated kinase-substrate meta-databases complemented with the NetworKIN in-silico prediction tool. For the proof of concept, we used human myeloid cell lines (K562, NB4, THP1, OCI-AML3, MOLM13 and MV4-11) with known oncogenic drivers and exposed them to clinically established kinase-inhibitors. Results: Biologically meaningful over- and under-active kinases were identified by KAEA in the unperturbed human myeloid cell lines (K562, NB4, THP1, OCI-AML3 and MOLM13). To increase the inhibition signal of the driving oncogenic kinases, we exposed the K562 (BCR-ABL1) and MOLM13/MV4-11 (FLT3-ITD) cell lines to either Nilotinib or Midostaurin kinase inhibitors, respectively. We observed correct detection of expected direct (ABL, KIT, SRC) and indirect (MAPK) targets of Nilotinib in K562 as well as indirect (PRKC, MAPK, AKT, RPS6K) targets of Midostaurin in MOLM13/MV4-11, respectively. Moreover, our pipeline was able to characterize unexplored kinase-activities within the corresponding signaling networks. Conclusions: We developed and validated a novel KAEA pipeline for the analysis of differential phosphoproteomics MS profiling data. We provide translational researchers with an improved instrument to characterize the biological behavior of kinases in response or resistance to targeted treatment. Further investigations are warranted to determine the utility of KAEA to characterize mechanisms of disease progression and treatment failure using primary patient samples.

Quantitative phosphoproteomics-based molecular network description for high-resolution kinase-substrate interactome analysis

Systematic Analysis of Protein Phosphorylation Networks From Phosphoproteomic Data

Quantitative phosphoproteomics strategies for understanding protein kinase-mediated signal transduction pathways

Phosphomatics: interactive interrogation of substrate–kinase networks in global phosphoproteomics datasets

Phosphorylated Protein Chip Combined with Artificial Intelligence Tools for Precise Drug Screening

Improving the Performance of Protein Kinase Identification Via High Dimensional Protein-Protein Interactions and Substrate Structure Data

Inferring the Sign of Kinase-Substrate Interactions by Combining Quantitative Phosphoproteomics with a Literature-Based Mammalian Kinome Network

Phosphopredict: A Bioinformatics Tool for Prediction of Human Kinase-Specific Phosphorylation Substrates and Sites by Integrating Heterogeneous Feature Selection

Phosphoproteomics data-driven signalling network inference: does it work?

Phosphoproteomics‐based Network Medicine

Targeted proteomics analyses of phosphorylation-dependent signalling networks

Quantitative phosphoproteomics by mass spectrometry: past, present, and future

Illuminating the Dark Cancer Phosphoproteome Through a Machine-Learned Co-Regulation Map of 26,280 Phosphosites

PhosNetVis: a web-based tool for fast kinase-substrate enrichment analysis and interactive 2D/3D network visualizations of phosphoproteomics data

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA)

Construction and Analysis of Human Phosphorylation Network

Reconstructing kinase network topologies from phosphoproteomics data reveals cancer-associated rewiring

diaPASEF-Powered Chemoproteomics Enables Deep Kinome Interaction Profiling

Data-driven extraction of human kinase-substrate relationships from omics datasets

A Targeted Quantitative Proteomics Strategy for Global Kinome Profiling of Cancer Cells and Tissues

µPhos: a scalable and sensitive platform for high-dimensional phosphoproteomics